Perrigo Gains 180-Day Exclusivity With ANDA Approval For Omeprazole Magnesium PPI
This article was originally published in The Tan Sheet
Executive Summary
Perrigo receives approval for its ANDA for a Prilosec OTC equivalent and another for a generic of Advil Fast Relief. The firm includes those products in its outlook for $1 billion in new product sales over three years.
You may also be interested in...
US OTC Decisions In June: Third Tentative Approval For Omeprazole Delayed Release ANDA, More Esomeprazole PPI Final Approvals
FDA told P&L Development, as it had with Aurobindo Pharma and Hetero Drugs, that its ANDA for a generic of Prilosec OTC delayed release is tentatively approved because exclusivity has not expired for Perrigo's first-approved generic of the PPI.
OTC Decisions Tracker: Dr Reddys NRT Lozenge Approved, Prilosec OTC And Monistat Packaging Revised
HBW Insight introduces an ongoing feature with information on decisions by FDA on NDAs and ANDA for nonprescription drugs and on sNDAs for label and package changes for approved OTC products. Dr Reddys Laboratories' clearance to launch OTC nicotine replacement therapy lozenges in the US and revisions to Prilosec OTC and Monistat packaging were among FDA's s OTC-related decisions in January.
Dr. Reddy’s Competition For Perrigo’s Omeprazole Delayed Six Months
Private label leader Perrigo should have an additional six months without competition from Dr. Reddy's against the firm's top-selling OTC product, the proton pump inhibitor omeprazole